Inhibiting angiogenesis in breast cancer: The beginning of the end or the end of the beginning?

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 898-901

  Rugo, Hope S ^a   Diller, Helen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EVEROLIMUS; LAPATINIB; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANGIOGENESIS; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; ERYTHEMA; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MICROANGIOPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN CARCINOMA; TUMOR GROWTH; BREAST TUMOR; FEMALE; LUNG CARCINOMA; NOTE; PAGET NIPPLE DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS;

EID: 84860617391     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.5492     Document Type: Editorial

References (25)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
3. Loges S, Mazzone M, Hohensinner P, et al: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15:167-170, 2009
4. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
5. Mancuso MR, Davis R, Norberg SM, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621, 2006 (Pubitemid 44511625)
6. Loges S, Schmidt T, Carmeliet P: Mechanisms of resistance to antiangiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1:12-25, 2010
7. Bergh J, Bondarenko IM, Lichinitser MR, et al: First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol 30:921-929, 2012
8. Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
9. Robert F, Sandler A, Schiller JH, et al: Sunitinib in combination with docetaxel in patients with advanced solid tumors: A phase I dose-escalation study. Cancer Chemother Pharmacol 66:669-680, 2010
10. Crown J, Dieras V, Staroslawska E, et al: Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 28:949s, 2010 (suppl 15; abstr LBA1011)
11. Robert NJ, Saleh MN, Paul D, et al: Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 11:82-92, 2011
12. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
13. Mayer EL, Dhakil S, Patel T, et al: SABRE-B: An evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 21:2370-2376, 2010
14. Curigliano G, Pivot X, Cortes J, et al: A randomized phase II study of sunitinib vs. standard of care for patients with previously treated advanced triple-negative breast cancer. Cancer Res 70:451s, 2010
15. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
16. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
17. Smith IE, Pierga JY, Biganzoli L, et al: First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2,251 patients. Ann Oncol 22:595-602, 2011
18. Miles D, Chan A, Romieu G, et al: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO. J Clin Oncol 26:43s, 2008 (suppl 15; abstr 1011)
19. Brufsky A, Rivera RR, Hurvitz SA, et al: Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 28:119s, 2010 (suppl 15; abstr 1021)
20. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
21. Bear HD, Tang G, Rastogi P, et al: Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366:310-320, 2012
22. von Minckwitz G, Eidtmann H, Rezai M, et al: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299-309, 2012
23. Gianni L, Romieu G, Lichinistser M, et al: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 71:S4-S8, 2011 (suppl 24)
24. An SJ, Huang YS, Chen ZH, et al: Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol [epub ahead of print on April 3, 2011]
25. Peppercorn J, Shapira I, Collyar D, et al: Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol 28:2635-2640, 2010